Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
- Results indicate a clinically meaningful improvement in OS with maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation and support the use of maintenance olaparib to achieve long-term remission in this setting; the potential for cure may also be enhanced.
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
- Trametinib represents a new standard-of-care option for patients with recurrent low-grade serous ovarian carcinoma.
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
- An infiltrative growth pattern infers poor prognosis within 2 years from diagnosis and may help select stage I patients for adjuvant therapy.
- High expression of THBS2 and TAGLN in mucinous ovarian cancer confers an adverse prognosis
- Anti-HER2 therapy should be investigated in a subset of patients.
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behaviour and Outcomes.
- Data showed two clear cell ovarian cancer subtypes:
:- One dominated by ARID1A-mutated tumors with enriched expression of canonical clear cell ovarian cancer genes and markers of platinum resistance;
:- The second was largely comprised of tumors with TP53 mutations and enriched for the expression of genes involved in extracellular matrix organization and mesenchymal differentiation.
- These two distinct molecular subclasses showed distinct clinical presentation and outcomes, with potential relevance to therapeutic responsiveness.